About Technology Issues FAQ

Links

Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)

Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.